Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | GOT1 | P17174 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20062878 | 0.74 | SMN1; SMN2 (0.53) | ALDH1A1HTTHSD17B10CYP1A2 | |
| SCHEMBL20071765 | 0.73 | SLC6A7 (0.34) | SLC6A7GOT1SCN9AOPRM1OPRL1 | |
| SCHEMBL27712781 | 0.69 | HPGD (0.36) | SLC6A7SCN9A | |
| SCHEMBL28770763 | 0.67 | ROCK1 (0.55) | SCN9AALDH1A1HTTHSD17B10 | |
| SCHEMBL3148048 | 0.67 | GOT1 (0.37) | SLC6A7GOT1OPRM1OPRL1CYP17A1 | |
| SCHEMBL17104832 | 0.67 | GOT1 (0.37) | SLC6A7GOT1SCN9AOPRM1OPRL1 | |
| SCHEMBL20062939 | 0.67 | RPS6KA5 (0.42) | TLR9CYP17A1CYP1A2 | |
| SCHEMBL20062935 | 0.65 | L3MBTL1 (0.46) | SLC6A7SCN9AALDH1A1CYP17A1CYP1A2 | |
| SCHEMBL10377958 | 0.65 | ADORA2A (0.35) | SLC6A7GOT1SCN9AOPRM1OPRL1 | |
| SCHEMBL20062943 | 0.65 | TLR9 (0.34) | TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | CANON KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180108691-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | BRD1, DRD1, NR2E3 | SLC6A7 4237/4885GOT1 4179/4885SCN9A 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.